Literature DB >> 31347999

Characterization of Escherichia coli obtained from patients undergoing peritoneal dialysis and diagnosed with peritonitis in a Brazilian centre.

Regiane C B Dias1, Melissa A Vieira1, Ana C Moro1, Danilo F M Ribolli1, Aydir C M Monteiro1, Carlos H Camargo2, Monique R Tiba-Casas2, Flávia B Soares2, Luis F Dos Santos2, Augusto C Montelli3,1, Maria de Lourdes R de S da Cunha1, Pasqual Barretti3, Rodrigo T Hernandes1.   

Abstract

Purpose. This study aimed to characterize 27 Escherichia coli isolates obtained from peritoneal dialysis (PD)-related peritonitis that occurred at the University Hospital of Botucatu Medical School, Brazil, between 1997 and 2015.Methodology. These isolates were characterized regarding the occurrence of 22 virulence factor-encoding genes, antimicrobial resistance and biofilm production. We then evaluated whether these factors influenced the clinical outcome.Results. Over an 18-year period, 726 episodes of PD-related peritonitis were diagnosed, with 27 of them (3.7 %) being due to E. coli. The majority of the isolates were classified in phylogroups B1 (33.3 %), B2 (30.0 %) or F (18.0 %). fimH (100.0 %), ompT (66.7 %) and irp2 (51.9 %) were the most prevalent genes, while papA, papC, iha, sat, irp2, iucD, ireA, ibe10, ompT and kpsMTII were significantly more prevalent among isolates belonging to phylogroups B2 and F (P<0.05). Non-susceptibility to quinolones was detected in six isolates, which harboured chromosomal and/or plasmid-mediated quinolone resistance determinants, while two CTX-M extended-spectrum β-lactamase-producing E. coli were identified. Virulence factor-encoding genes (alone or in combination) and antimicrobial resistance were not associated with non-resolution outcomes. However, there was a trend for the ability to produce biofilm to be associated with treatment failure, although this association was not statistically significant.Conclusion. The E. coli isolates were heterogeneous in terms of the features investigated, and were susceptible to most of the antimicrobial drugs tested, despite the unsuccessful treatment observed in more than 50.0 % of the patients. Studies including more cases could help to clarify if biofilm production can influence the outcome in patients with PD-related peritonitis.

Entities:  

Keywords:  Escherichia coli; antimicrobial resistance; peritoneal dialysis; peritonitis; virulence factors

Mesh:

Substances:

Year:  2019        PMID: 31347999     DOI: 10.1099/jmm.0.001043

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  Comparison of clinical features and outcomes in peritoneal dialysis-associated peritonitis patients with and without diabetes: A multicenter retrospective cohort study.

Authors:  Ling-Fei Meng; Li-Ming Yang; Xue-Yan Zhu; Xiao-Xuan Zhang; Xin-Yang Li; Jing Zhao; Shi-Chen Liu; Xiao-Hua Zhuang; Ping Luo; Wen-Peng Cui
Journal:  World J Diabetes       Date:  2020-10-15

Review 2.  Extended-Spectrum Beta-Lactamases Producing Escherichia coli in South America: A Systematic Review with a One Health Perspective.

Authors:  Carlos Bastidas-Caldes; Daniel Romero-Alvarez; Victor Valdez-Vélez; Roberto D Morales; Andrés Montalvo-Hernández; Cicero Gomes-Dias; Manuel Calvopiña
Journal:  Infect Drug Resist       Date:  2022-09-30       Impact factor: 4.177

3.  Characterization of Uropathogenic Escherichia coli Reveals Hybrid Isolates of Uropathogenic and Diarrheagenic (UPEC/DEC) E. coli.

Authors:  Rodrigo H S Tanabe; Regiane C B Dias; Henrique Orsi; Daiany R P de Lira; Melissa A Vieira; Luís F Dos Santos; Adriano M Ferreira; Vera L M Rall; Alessandro L Mondelli; Tânia A T Gomes; Carlos H Camargo; Rodrigo T Hernandes
Journal:  Microorganisms       Date:  2022-03-17

4.  Peritoneal dialysis-related peritonitis caused by gram-negative organisms: ten-years experience in a single center.

Authors:  Ying Zeng; Linsen Jiang; Ying Lu; Zhi Wang; Kai Song; Huaying Shen; Sheng Feng
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.